NZYM B Novozymes A/S Class B

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting

The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark.

For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals.

BOARD OF DIRECTORS

The Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Dalsgaard as Vice Chair, both for a one-year term.

In addition, the Board of Directors proposes the re-election of all shareholder-elected members of the Board of Directors, each for a one-year term: Lise Kaae, Monila Kothari, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer and Kim Stratton.

A detailed description of each of the nominated candidates’ competencies, managerial positions in other companies etc. is included in Appendix 1 to this invitation.

Attachments



EN
26/02/2026

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

March 26, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Resolutions from the Annual General Meeting 2026

Resolutions from the Annual General Meeting 2026 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025Approval of the Remuneration Report for 2025 (advisory vote)Approval of the remuneration of membe...

March 23, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

March 23, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO...

March 16, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis issues EUR 1.7 billion senior unsecured notes On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026. The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%. ...

March 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch